Previous 10 | Next 10 |
Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Sy...
The shares of Natera ( NASDAQ: NTRA ) and Myriad Genetics ( NASDAQ: MYGN ) climbed, and those of Exact Sciences ( NASDAQ: EXAS ) and Veracyte ( NASDAQ: VCYT ) fell in pre-market Wednesday after Raymond James changed its ratings in the gene-based diagnostic space. ...
New predictive data evaluates patient outcomes up to 24.8 months post-surgery, confirms findings presented at ASCO GI 2022 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine , which demonst...
Summary Despite its price surge, EXAS's valuation remains aligned with industry averages. EXAS has one of the clearest profitability paths in a market characterized by heavy losses stemming from aggressive growth initiatives. We might see some profit-taking in the coming weeks, but ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 at 9:45 a.m. PT (12:45 p.m. ET). Members of Natera management will deliver a present...
Summary Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth. Even if management succee...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced its support for a recent guideline update by the International Society for Heart and Lung Transplantation (ISHLT), which includes the use of donor-derived cfDNA (dd-cfDNA) testing for surveillance of heart ...
Summary CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions warrant a rating upgrade. The company has a strong balance sheet, with enough dry powder to leverage itself into profitability a...
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers PR Newswire Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time w...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...